BREAKING NEW THERAPEUTIC GROUNDS: FUSION PROTEINS OF DARPINS AND OTHER NONANTIBODY BINDING PROTEINS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 506

27. Lux SE, John KM, Bennett V. (1990) Analysis of cDNA for
human erythrocyte ankyrin indicates a repeated structure with
homology to tissue-differentiation and cell-cycle control pro-
teins. Nature 344, 36-42.
28. Sotomayor M, Corey DP, Schulten K. (2005) In search of the
hair-cell gating spring elastic properties of ankyrin and cad-
herin repeats. Structure 13, 669-682.
29. Letunic I, Doerks T, Bork P. (2009) SMART 6: recent updates
and new developments. Nucleic Acids Res. 37, D229-232.
30. Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R,
Nagy-Davidescu G, et al. (2010) Efficient tumor targeting with
high-affinity designed ankyrin repeat proteins: effects of affin-
ity and molecular size. Cancer Res. 70, 1595-1605.
31. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC,
McKern NM, et al. (2007) A designed ankyrin repeat protein
evolved to picomolar affinity to Her2. J. Mol. Biol. 369, 1015-
1028.
32. Sennhauser G, Grutter MG. (2008) Chaperone-assisted crys-
tallography with DARPins. Structure 16, 1443-1453.
33. Theurillat JP, Dreier B, Nagy-Davidescu G, Seifert B, Behnke
S, Zurrer-Hardi U, et al. (2010) Designed ankyrin repeat
proteins: a novel tool for testing epidermal growth factor
receptor 2 expression in breast cancer. Mod. Pathol. 23,
1289-1297.
34. Amstutz P, Binz HK, Parizek P, Stumpp MT, Kohl A, Grutter
MG, et al. (2005) Intracellular kinase inhibitors selected from
combinatorial libraries of designed ankyrin repeat proteins. J.
Biol. Chem. 280, 24715-24722.
35. Sennhauser G, Amstutz P, Briand C, Storchenegger O, Grutter
MG. (2007) Drug export pathway of multidrug exporter AcrB
revealed by DARPin inhibitors. PLoS Biol. 5, e7.
36. Schweizer A, Roschitzki-Voser H, Amstutz P, Briand C,
Gulotti-Georgieva M, Prenosil E, et al. (2007) Inhibition of
caspase-2 by a designed ankyrin repeat protein: specificity,
structure, and inhibition mechanism. Structure 15, 625-636.
37. Steiner D, Forrer P, Pluckthun A. (2008) Efficient selection of
DARPins with sub-nanomolar affinities using SRP phage
display. J. Mol. Biol. 382, 1211-1227.
38. Stumpp MT, Amstutz P. (2007) DARPins: a true alternative to
antibodies. Curr. Opin. Drug Discov. Dev. 10, 153-159.
39. Stumpp MT, Binz HK, Amstutz P. (2008) DARPins: a new
generation of protein therapeutics. Drug Discov. Today 13,
695-701.
40. Eggel A, Baumann MJ, Amstutz P, Stadler BM, Vogel M.
(2009) DARPins as bispecific receptor antagonists analyzed
for immunoglobulin E receptor blockage. J. Mol. Biol. 393,
598-607.

41. Schlehuber S, Skerra A. (2001) Duocalins: Engineered Lig-
and-Binding Proteins with Dual Specificity Derived from the
Lipocalin Fold. Biol. Chem. 382, 1335-1342.
42. Friedman M, Lindstrom S, Ekerljung L, Andersson-Svahn H,
Carlsson J, Brismar H, et al. (2009) Engineering and charac-
terization of a bispecific HER2 x EGFR-binding affibody
molecule. Biotechnol. Appl. Biochem. 54, 121-131.
43. Emanuel SL, Engle LJ, Chao G, Zhu RR, Cao C, Lin Z, et al.
(2011) A fibronectin scaffold approach to bispecific inhibitors
of epidermal growth factor receptor and insulin-like growth
factor-I receptor. mAbs 3, 38-48.
44. Dreier B, Mikheeva G, Belousova N, Parizek P, Boczek E,
Jelesarov I, et al. (2011) Her2-specific multivalent adapters
confer designed tropism to adenovirus for gene targeting. J.
Mol. Biol. 405, 410-426.
45. Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D,
Waibel R, et al. (2003) A recombinant immunotoxin derived
from a humanized epithelial cell adhesion molecule-specific
single-chain antibody fragment has potent and selective anti-
tumor activity. Clin. Cancer Res. 9, 2837-2848.
46. Kaspar M, Zardi L, Neri D. (2006) Fibronectin as target for
tumor therapy. Int. J. Cancer 118, 1331-1339.
47. Martin-Killias P, Stefan N, Rothschild S, Pluckthun A,
Zangemeister-Wittke U. (2011) A novel fusion toxin derived
from an EpCAM-specific designed ankyrin repeat protein has
potent antitumor activity. Clin. Cancer Res. 17, 100-110.
48. Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson FY,
Stahl S, et al. (2005) In vitro characterization of a bivalent anti-
HER-2 affibody with potential for radionuclide-based diag-
nostics. Cancer Biother. Radiopharm. 20, 239-248.
49. Tolmachev V, Friedman M, Sandstrom M, Eriksson TL, Rosik
D, Hodik M, et al. (2009) Affibody molecules for epidermal
growth factor receptor targeting in vivo: aspects of dimeriza-
tion and labeling chemistry. J. Nucl. Med. 50, 274-283.
50. Tolmachev V, Wallberg H, Andersson K, Wennborg A,
Lundqvist H, Orlova A. (2009) The influence of Bz-DOTA
and CHX-A 00 -DTPA on the biodistribution of ABD-fused anti-
HER2 Affibody molecules: implications for (114m)In-medi-
ated targeting therapy. Eur. J. Nucl. Med. Mol. Imaging 36,
1460-1468.
51. Jonsson A, Wallberg H, Herne N, Stahl S, Frejd FY. (2009)
Generation of tumour-necrosis-factor-alpha-specific affibody
molecules capable of blocking receptor binding in vitro.
Biotechnol. Appl. Biochem. 54, 93-103.
52. Silverman J, Liu Q, Lu Q, Bakker A, To W, Duguay A, et al.
(2005). Multivalent avimer proteins evolved by exon shuffling
of a family of human receptor domains. Nat. Biotechnol. 23,
1556-1561.